2018

February 28, 2018

Year-end report 2017

 

April 12, 2018

Annual Report 2017

 

May 15, 2018

  • Interim report January-March 2018
  • AGM: The annual general meeting for IBT will be held on May 15th 2018 at 15.00 CET . The last date to request that a matter be put before the annual general meeting is March 28, 2018.

 

August 23, 2018

Interim report January-June 2018

 

November 21, 2018

Interim report January-September 2018

 

 

2017

April 2017

Annual Report 2016

 

May 4, 2017

– Annual General Meeting will be held at Citykonferensen Ingenjörshuset, Malmskillnadsgatan 46, 111 84 Stockholm, at 14:00.

See Annual General Meeting 2017 for more information

Interim report January-March 2017

 

August 28, 2017

Interim report January-June 2017

 

September 7, 2017

Pareto Securities’ 8th Annual Health Care Seminar in Stockholm

 

September 8, 2017

Capital Markets Day

IBT welcomes investors, representatives from the financial markets and media to our Capital Markets Day in Stockholm on Friday September 8, 2017, starting at 9.30 and ending at approximately 12.00 at Svenska Läkaresällskapet, Klara Östra Kyrkogata 10, Stockholm.

The purpose of the Capital Markets Day is to present Infant Bacterial Therapeutics business, information about the disease necrotizing enterocolitis, the IBP-9414 project, gastroschisis and the IBP-1016 project.

 

Introduction

Peter Rothschild, Chairman of the Board, IBT 

Staffan Strömberg PhD, Chief Executive Officer, IBT

What is Necrotizing Enterocolitis  

Professor Josef Neu MD, Department of Pediatrics, Division of Neonatology,  Univ. Florida, Gainesville  

Why IBP-9414 for Necrotizing Enterocolitis

Gastroschisis and IBP-1016 – A New Opportunity

Eamonn Connolly PhD, Chief Scientific Officer, IBT

Pharmaceutical Development of IBP-9414 – Breaking New Ground

Agneta Heierson PhD, Vice President, Clinical Development, IBT  

Anders Kronström M.Sc., M.B.A., Chief Technical Officer, IBT

A Globally Valuable Pharmaceutical

Daniel Mackey, Chief Financial Officer, IBT

Closing Remarks 

Staffan Strömberg PhD, Chief Executive Officer, IBT

 

Attendance: If you would like to participate in the event, please register by sending a mail to ibt@ibtherapeutics.com

 

November 23, 2017

Interim report January-September 2017